In parallel, virtually all MS patients have been infected with EBV, and meta-analyses show EBV seropositivity alone confers ~2.6-fold MS risk, which is further amplified in HLA-DRB1*15:01 carriers [74]. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.